Skip to main content
SpringerLink
Log in

Suramin Sodium

CI 1003, Metaret®, Suramin, Suramin Hexasodium

  • Section 2: Men’s Health
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Falcone A, Antonuzzo A, Danesi R, et al. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 1999 Aug 1; 86: 470–6

    Article  PubMed  CAS  Google Scholar 

  2. Kobayashi K, Vokes EE, Vogelzang NJ, et al. Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 1995 Sep; 13: 2196–207

    PubMed  CAS  Google Scholar 

  3. Arit W, Reincke M, Siekmann L, et al. Suramin in adrenocortical cancer: limited efficacy and serious toxicity. Clin Endocrinol 1994 Sep; 41: 299–307

    Article  Google Scholar 

  4. Bowden CJ, Figg WD, Dawson NA, et al. Aphase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response. Cancer Chemother Pharmacol 1996 Nov–Dec; 39: 1–8

    Article  PubMed  CAS  Google Scholar 

  5. Bitton RJ, Figg WD, Venzon DJ, et al. Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol 1995 Sep; 13: 2223–9

    PubMed  CAS  Google Scholar 

  6. Mirza MR, Jakobsen E, Pfeiffer P, et al. Suramin in non-small cell lung cancer and advanced breast cancer: two parallel phase II studies. Acta Oncologica 1997; 36 No. 2: 171–4

    Article  PubMed  CAS  Google Scholar 

  7. Woll PJ, Ranson M, Margison J, et al. Suramin for breast and prostate cancer: a pilot study of intermittent short infusions without adaptive control. Ann Oncol 1994 Sep; 5: 597–600

    PubMed  CAS  Google Scholar 

  8. Cole DJ, Ettinghausen SE, Pass HI, et al. Postoperative complications in patients receiving suramin therapy. Surgery 1994 Jul; 116: 90–5

    PubMed  CAS  Google Scholar 

  9. Eisenberger MA, Sinibaldi VJ, Reyno LM, et al. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 1995 Sep; 13: 2174–86

    PubMed  CAS  Google Scholar 

  10. Dawson NA, Figg WD, Cooper MR, et al. Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer. J Clin Oncol 1997 Apr; 15: 1470–7

    PubMed  CAS  Google Scholar 

  11. Piscitelli SC, Forrest A, Lush RM, et al. Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics. Pharmacotherapy 1997 May–Jun; 17: 431–7

    PubMed  CAS  Google Scholar 

  12. Kloen P, Jennings CL, Gebhardt MC, et al. Suramin inhibits growth and transforming growth factor-beta-1 (TGF-beta-1) binding in osteosarcoma cell lines. Eur J Cancer 1994; 30 (5 Pt A): 678–82

    Article  Google Scholar 

  13. Lindman H, Taube A, Bergh JCS. Suramin inhibits the growth of human breast cancer cell lines. Studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-glycoprotein. Anticancer Res 1994 Mar–Apr; 14 (2A): 363–6

    PubMed  CAS  Google Scholar 

  14. Lopez Lopez R, van Rijswijk REN, Wagstaff J, et al. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin. Eur J Cancer 1994; 30 (10 Pt A): 1545–9

    Article  Google Scholar 

  15. Kikuchi Y, Hirata J, Hisano A, et al. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II). Gynecol Oncol 1995 Jul; 58: 11–5

    Article  PubMed  CAS  Google Scholar 

  16. Small EJ, Marshall ME, Reyno L, et al. Superiority of suramin plus hydrocortisone over placebo plus hydrocortisone: results of a multi-center double-blind phase III study in patients with hormone refractory prostate cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 16–18; Los Angeles, 17: 308

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suramin Sodium. Drugs R&D 2, 431–435 (1999). https://doi.org/10.2165/00126839-199902060-00018

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902060-00018

Keywords

Search

Navigation